Freestone Grove Partners LP Takes Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Freestone Grove Partners LP acquired 2.17 million Elanco shares valued at approximately $53.4 million, giving it a 0.43% stake. Institutional investors collectively own 97.48% of the company.
• Elanco exceeded quarterly expectations, reporting $0.34 in EPS versus the $0.27 consensus and $1.37 billion in revenue, up 10.2% year over year. The company guided to full-year 2026 EPS of $1.10–$1.16.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $29.09 versus the reported share price of $25.09; company insiders have also purchased shares recently.

Freestone Grove Partners LP acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 2,170,681 shares of the company's stock, valued at approximately $53,420,000. Freestone Grove Partners LP owned about 0.43% of Elanco Animal Health at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. NewEdge Advisors LLC grew its holdings in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at $38,000. Root Financial Partners LLC grew its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after buying an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health during the 4th quarter worth $41,000. Finally, Torren Management LLC acquired a new stake in Elanco Animal Health during the 4th quarter worth $46,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

ELAN opened at $25.09 on Thursday. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The business has a 50 day moving average price of $24.61 and a two-hundred day moving average price of $24.01. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market cap of $12.54 billion, a PE ratio of -61.20, a P/E/G ratio of 1.50 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same period last year, the business posted $0.26 EPS. The company's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. Citigroup upped their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, August 20th. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. UBS Group raised their price target on Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, Wall Street Zen lowered Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.09.

Insider Buying and Selling

In other news, Director Paul Herendeen bought 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the purchase, the director owned 111,687 shares of the company's stock, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares of the company's stock, valued at approximately $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 63,198 shares of company stock worth $1,473,109 in the last ninety days. Insiders own 1.14% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source